Latigo is a cash-burning speculative biotech with quality at 1.4, a Piotroski score of 0 of 9 and deeply negative momentum, partly offset by $5.04M of insider buying; the headline 227% analyst upside rests on a target the engine rejected as implausible.
Thesis pillars
- Quality Below Minimum Floor↓Deteriorating
- Large Earnings Miss→Stable
- Notable Insider Buying↑Improving
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Oct 11, 2026
Latigo Biotherapeutics, Inc. (LTGO) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $14.04: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum.
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of... Read more
Sell if holding. Engine safety override at $14.04: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.5/10, moderate confidence.
Passes 5/8 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and earnings proximity 7d<=7d. Suitability: speculative.
Recent developments
updated Nov 4, 2026Recent Developments — Latigo Biotherapeutics, Inc.
Latest news
- NEWS Latigo Biotherapeutics Announces Participation in Upcoming Investor Conferences — fiscal.ai Nov 4, 2026 neutral
- NEWS 'Trump Administration Backs Down on an Opioid Ban After Kratom Industry Lobbying' - NY Times — benzinga Oct 28, 2026 neutral
- NEWS Latigo Biotherapeutics Q2 EPS $(27.59) Up From $(36.52) YoY, Sales $0.00, Same YoY — benzinga Sep 3, 2026 negative
- NEWS Leerink Partners Initiates Coverage On Latigo Biotherapeutics with Outperform Rating, Announces Price Target of $36 — benzinga Sep 1, 2026 positive
- NEWS Jefferies Initiates Coverage On Latigo Biotherapeutics with Buy Rating, Announces Price Target of $50 — benzinga Sep 1, 2026 positive
Latest item Nov 4, 2026 · Generated 2026-11-05T12:04:09Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
4 floor-breakers
Quality below the gate floor. Component breakdown shows what dragged the score down.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $14.04: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $13.06. Score 4.5/10, moderate confidence.
Resistance target: $17.32 (+23.4% upside). Prior stop was $13.06. Stop-loss: $13.06.
DATA_ISSUE: analyst_target_implausible (raw $52.25 vs price $14.04 — ratio 3.7×). Rejected, falling back to technical TP.; Quality below floor (1.4 < 4.0).
Latigo Biotherapeutics, Inc. trades at a P/E of N/A (forward -6.7). TrendMatrix value score: 5.0/10. Verdict: Sell.
8 analysts rate LTGO, with a consensus score of 4.3/5. 4 analysts publish price targets averaging $52.
What does Latigo Biotherapeutics, Inc. do?Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the...
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting with osteoarthritis; and LTG-418, a NaV1.8 inhibitor developed for the treatment of acute and chronic pain. Latigo Biotherapeutics, Inc. was formerly known as WVB-Desmond, Inc. and changed its name to Latigo Biotherapeutics, Inc. in March 2019. Latigo Biotherapeutics, Inc. was incorporated in 2018 and is based in Thousand Oaks, California.